Hold Rating on Akoya Biosciences Amid Acquisition Uncertainties and Financial Challenges

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Hold rating on Akoya Biosciences (AKYA – Research Report), retaining the price target of $3.50.

Kyle Mikson CFA has given his Hold rating due to a combination of factors impacting Akoya Biosciences. The company’s recent financial performance showed a decline in instrument revenue due to capital purchasing constraints, although overall revenue was in line with expectations. Despite a sequential decrease in cash burn and improved gross margins driven by operational efficiency, Akoya did not provide 2025 financial guidance due to its pending acquisition by Quanterix.
Furthermore, uncertainties surrounding NIH funding could negatively affect Akoya’s academic research business. While the merger with Quanterix presents a value proposition, investor skepticism about the deal’s synergies and the potential challenges in realizing near- to medium-term benefits contribute to the Hold rating. The anticipated muted share price performance until the shareholder and merger vote further supports this cautious stance.